Continued margin expansion allowed Teva to hit its bottom line and cash flow targets in 2021 amid declining revenues, including softer North America generics sales mainly due to a lack of significant product launches during the year.
Taking in the 2021 financial results overall, president and CEO Kåre Schultz insisted, “I am expecting that 2022 will be...








